This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Treacy EP et al. Treatment of genetic disease. In: The Metabolic Basis of Inherited Disease, ed. Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D. 8th Edn. McGraw Hill: New York 2003: 175–192.
Weatherall DJ, Clegg JB The Thalassaemia Syndromes, 4th Edn. Blackwell Scientific Publishers: Oxford 2001.
Atweh GF, Schechter AN . Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr Opin Hematol 2001; 8: 123–130.
Ley TJ et al. 5-Azacytidine increases γ-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 1983; 62: 370–380.
Platt OS et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984; 74: 652–656.
Charache S et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Eng J Med 1995; 332: 1317–1322.
Steinberg MH et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia. Risks and benefits up to 9 years of treatement. J Am Med Assoc 2003; 289: 1645–1651.
Mentzer W . Bone marrow transplantation for haemoglobinopathies. Curr Opin Hematol 2000; 7: 95–100.
Bradai M et al. Hydroxyurea can eliminate transfusion requirements in children with severe beta thalassemia. Blood 2003; 102: 1529–1530.
Olivieri NF et al. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet 1997; 350: 491–492.
Atweh GF et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999; 93: 1790–1797.
DeSimone J et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 2002; 99: 3905–3908.
Orringer EP et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease. A randomized controlled trial. J Am Med Assoc 2001; 286: 2099–2106.
Deconinck N et al. Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice. Nat Med 1997; 3: 1216–1221.
Weatherall DJ . Phenotype–genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2001; 2: 245–255.
Author information
Authors and Affiliations
Corresponding author
Additional information
DUALITY OF INTEREST
None.
Rights and permissions
About this article
Cite this article
Weatherall, D. Pharmacological treatment of monogenic disease. Pharmacogenomics J 3, 264–266 (2003). https://doi.org/10.1038/sj.tpj.6500198
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500198
This article is cited by
-
The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst
Journal of Negative Results in BioMedicine (2005)